Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's I-Mab Raises $220 Million in C Round for Biotech Development

publication date: Jun 29, 2018

China's I-Mab Biopharma completed a $220 million Series C round led by Hony Capital. It was, according to the company, one of the largest C rounds ever for an innovative China biotech. I-Mab was formed in early 2017 when C-Bridge Capital and Tasly Pharma merged two China entities, Third Venture Biotech and Tasgen Bio, and invested $150 million in the consolidated company. At the time, I-Mab was said to have twelve antibody drug candidates. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital